PTCT:NGS-PTC Therapeutics Inc. (USD)

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing

USD 38.85

Change

-1.27 (-3.17)%

Market Cap

USD 0.40B

Volume

1.36M

Analyst Target

USD 60.30
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

PTC Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of orally administered, proprietary small-molecule drugs that target post-transcriptional control processes.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-21 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+1.70 (+0.35%)

USD 124.65B
REGN Regeneron Pharmaceuticals Inc

+9.97 (+0.97%)

USD 110.51B
MRNA Moderna Inc

-5.20 (-3.58%)

USD 57.87B
BNTX BioNTech SE

-3.92 (-4.08%)

USD 24.18B
ARGX argenx NV ADR

-1.34 (-0.35%)

USD 23.09B
ALNY Alnylam Pharmaceuticals Inc

+0.34 (+0.21%)

USD 20.25B
GMAB Genmab AS

-0.22 (-0.83%)

USD 18.17B
BGNE BeiGene Ltd

-3.80 (-2.28%)

USD 17.74B
RPRX Royalty Pharma Plc

-0.28 (-1.03%)

USD 16.18B
BMRN Biomarin Pharmaceutical Inc

-0.73 (-0.87%)

USD 15.32B

ETFs Containing PTCT

MSGR 6.14 % 0.00 %

N/A

N/A
IBRN iShares Trust - iShares N.. 5.41 % 0.00 %

-0.33 (0.00%)

USD 3.84M
CDNA:CA CI Bio-Revolution ETF 3.19 % 0.00 %

N/A

CAD 5.88M
XBI SPDR® S&P Biotech ETF 1.29 % 0.35 %

-2.07 (0.00%)

USD 7.07B
LABU Direxion Daily S&P Biotec.. 0.75 % 1.14 %

-8.17 (0.00%)

USD 1.10B
BBP Virtus LifeSci Biotech Pr.. 0.00 % 0.79 %

-0.77 (0.00%)

USD 0.02B
GURU Global X Guru Index ETF 0.00 % 0.75 %

-0.39 (0.00%)

USD 0.04B
PBE Invesco Dynamic Biotechno.. 0.00 % 0.57 %

-0.54 (0.00%)

USD 0.26B
BIOT:LSE L&G PHARMA BREAKTHROUGH G.. 0.00 % 0.00 %

-0.09 (0.00%)

USD 8.18M
WELL:LSE Hanetf Icav - Han-Gins He.. 0.00 % 0.00 %

-0.07 (0.00%)

USD 0.02B
BIOT 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 40.97% 80% B- 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 40.97% 80% B- 88% B+
Trailing 12 Months  
Capital Gain -33.49% 45% F 26% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -33.49% 45% F 26% F
Trailing 5 Years  
Capital Gain -1.37% 72% C 52% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -1.37% 71% C- 44% F
Average Annual (5 Year Horizon)  
Capital Gain -4.59% 53% F 34% F
Dividend Return -4.59% 53% F 32% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 30.62% 83% B 60% D-
Risk Adjusted Return -14.99% 48% F 33% F
Market Capitalization 0.40B 91% A- 83% B

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A
Price/Book Ratio 1,743.27 0% 0%
Price / Cash Flow Ratio -16.30 89% 86%
Price/Free Cash Flow Ratio -10.22 87% 84%
Management Effectiveness  
Return on Equity -7,740.12% 0% 0%
Return on Invested Capital -35.51% 70% 27%
Return on Assets -10.29% 88% 34%
Debt to Equity Ratio -232.60% 93% 96%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector